Phase II clinical trial - Appareil urinaire
BLAD-RAD01 (GETUG-AFU V07)
Ouvert depuis le: 12.01.2023
Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy: a Prospective Randomized Comparative Phase II Trial.
Description de l'essai
This is a phase II, multicenter, randomized open-label and comparative study designed to evaluate whether local consolidative radiotherapy plus standard of care improves overall survival as compared to standard of care in patients with limited metastatic urothelial bladder cancer and without progression following the initial phase of first-line systemic therapy.;Each patient will be followed during 4 years from the date of randomization.